Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
Johnson and Johnson
Harvard Business School
McKesson

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR INTEGRILIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Integrilin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00089895 ↗ EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) Completed Duke Clinical Research Institute Phase 3 2004-11-01 The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide).
NCT00089895 ↗ EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2004-11-01 The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide).
NCT00250991 ↗ Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 1/Phase 2 2003-07-01 The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.
NCT00250991 ↗ Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial Completed University of Cincinnati Phase 1/Phase 2 2003-07-01 The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.
NCT00638976 ↗ INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial Completed Fondazione Evidence per AttivitĂ  e Ricerche Cardiovascolari ONLUS Phase 3 2007-11-01 Randomized, blind controlled, Multicenter, spontaneous, prospective trial, roughly 20 enrolling centers in Italy, placebo and active drug supply given by GlaxoSmithKline (GSK).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Integrilin

Condition Name

Condition Name for Integrilin
Intervention Trials
Acute Coronary Syndrome 3
Stroke 3
Brain Infarction 2
Myocardial Infarction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Integrilin
Intervention Trials
Infarction 6
Myocardial Infarction 5
Acute Coronary Syndrome 4
Stroke 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Integrilin

Trials by Country

Trials by Country for Integrilin
Location Trials
United States 37
Denmark 2
Italy 2
Poland 2
Finland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Integrilin
Location Trials
Ohio 5
New York 3
Michigan 3
Kentucky 3
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Integrilin

Clinical Trial Phase

Clinical Trial Phase for Integrilin
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 8
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Integrilin
Clinical Trial Phase Trials
Completed 10
Terminated 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Integrilin

Sponsor Name

Sponsor Name for Integrilin
Sponsor Trials
National Institute of Neurological Disorders and Stroke (NINDS) 3
University of Alabama at Birmingham 2
University of Cincinnati 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Integrilin
Sponsor Trials
Other 17
Industry 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Moodys
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.